|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing deposits | ||||||||||||||||||||
| Federal funds sold | ||||||||||||||||||||
| Resell agreements | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Securities held to maturity, net of allowance for credit losses of $500 at both June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Securities available for sale, at estimated fair value | ||||||||||||||||||||
| Trading account securities | ||||||||||||||||||||
| Loans, net of unearned discounts | ||||||||||||||||||||
| Less: Allowance for credit losses on loans | ||||||||||||||||||||
| Net loans | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Accrued interest receivable and other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Non-interest-bearing demand deposits | ||||||||||||||||||||
| Interest-bearing deposits | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Federal funds purchased | ||||||||||||||||||||
| Repurchase agreements | ||||||||||||||||||||
| Junior subordinated deferrable interest debentures, net of unamortized issuance costs | ||||||||||||||||||||
| Subordinated notes, net of unamortized issuance costs | ||||||||||||||||||||
| Accrued interest payable and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ Equity: | ||||||||||||||||||||
| Preferred stock, par value $0.01 per share; 10,000,000 shares authorized; 150,000 Series B shares ($1,000 liquidation preference) issued at both June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Common stock, par value $0.01 per share; 210,000,000 shares authorized; 64,404,582 shares issued at both June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive income (loss), net of tax | ||||||||||||||||||||
| Treasury stock, at cost; 2,255,936 shares at June 30, 2026 and 1,117,394 at December 31, 2025 | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
